Literature DB >> 32457410

Molecular patterns in salivary duct carcinoma identify prognostic subgroups.

Ruta Gupta1,2,3, Mark J Cowley4,5,6, Simon A Mueller7,8,9, Marie-Emilie A Gauthier1,4,5, James Blackburn10,6, John P Grady4, Spiridoula Kraitsek11, Elektra Hajdu4, Matthias S Dettmer12, Jane E Dahlstrom13, C Soon Lee14,15,16,17,2,3, Peter P Luk1,2, Bing Yu11,3, Roland Giger18, Sarah Kummerfeld4,6, Jonathan R Clark1,3,19.   

Abstract

Salivary duct carcinoma (SDCa) is a rare cancer with high rate of metastases and poor survival despite aggressive multimodality treatment. This study analyzes the genetic changes in SDCa, their impact on cancer pathways, and evaluates whether molecular patterns can identify subgroups with distinct clinical characteristics and outcome. Clinicopathologic details and tissue samples from 66 patients (48 males, 18 females) treated between 1995 and 2018 were obtained from multiple institutions. Androgen receptor (AR) was assessed by immunohistochemistry, and the Illumina TruSight 170 gene panel was used for DNA sequencing. Male gender, lympho-vascular invasion, lymph node metastasis, and smoking were significant predictors of disease-free survival. AR was present in 79%. Frequently encountered alterations were mutations in TP53 (51%), PIK3CA (32%) and HRAS (22%), as well as amplifications of CDK4/6 (22%), ERBB2 (21%), MYC (16%), and deletions of CDKN2A (13%). TP53 mutation and MYC amplifications were associated with decreased disease-free survival. Analysis of cancer pathways revealed that the PI3K pathway was most commonly affected. Alterations in the cell cycle pathway were associated with impaired disease-free survival (HR 2.6, P = 0.038). Three subgroups based on AR and ERBB2 status were identified, which featured distinct molecular patterns and outcome. Among AR positive SDCa, HRAS mutations were restricted to AR positive tumors without ERBB2 amplification and HRAS mutations featured high co-occurrence with PIK3CA alterations, which seems specific to SDCa. AR negative SDCa were associated with poor disease-free survival in multivariate analysis (HR 4.5, P = 0.010) and none of these tumors exhibited ERBB2 amplification or HRAS mutations. AR and ERBB2 status in SDCa thus classifies tumors with distinct molecular profiles relevant to future targeted therapy. Furthermore, clinical factors such as smoking and molecular features such as MYC amplification may serve as markers of poor prognosis of SDCa.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32457410     DOI: 10.1038/s41379-020-0576-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  48 in total

1.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

2.  Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.

Authors:  Peter P Luk; Jared D Weston; Bing Yu; Christina I Selinger; Rafael Ekmejian; Timothy J Eviston; Trina Lum; Kan Gao; Michael Boyer; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck       Date:  2015-12-24       Impact factor: 3.147

3.  Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.

Authors:  Jong Chul Park; T Martin Ma; Lisa Rooper; Todd Hembrough; Robert D Foss; Nicole C Schmitt; Rishi Sawhney; Aaron Flanders; Hyunseok Kang
Journal:  Head Neck       Date:  2018-11-26       Impact factor: 3.147

4.  Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database.

Authors:  Virginia Osborn; Babak Givi; Anna Lee; Niki Sheth; Dylan Roden; David Schwartz; David Schreiber
Journal:  Oral Oncol       Date:  2017-06-05       Impact factor: 5.337

Review 5.  Major and minor salivary gland tumors.

Authors:  Marco Guzzo; Laura D Locati; Franz J Prott; Gemma Gatta; Mark McGurk; Lisa Licitra
Journal:  Crit Rev Oncol Hematol       Date:  2009-11-24       Impact factor: 6.312

6.  Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.

Authors:  Margaret S Soper; Shawn Iganej; Lester D R Thompson
Journal:  Head Neck       Date:  2013-09-17       Impact factor: 3.147

7.  A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.

Authors:  Eline Boon; Miranda Bel; Wim van Boxtel; Winette T A van der Graaf; Robert J J van Es; Simone E J Eerenstein; Robert J Baatenburg de Jong; Michiel W M van den Brekel; Lilly-Ann van der Velden; Max J H Witjes; Ann Hoeben; Stefan M Willems; Elisabeth Bloemena; Laura A Smit; Sjoukje F Oosting; Marianne A Jonker; Uta E Flucke; Carla M L van Herpen
Journal:  Int J Cancer       Date:  2018-03-23       Impact factor: 7.396

8.  The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.

Authors:  Luc G T Morris; Raghu Chandramohan; Lyndsay West; Ahmet Zehir; Debyani Chakravarty; David G Pfister; Richard J Wong; Nancy Y Lee; Eric J Sherman; Shrujal S Baxi; Ian Ganly; Bhuvanesh Singh; Jatin P Shah; Ashok R Shaha; Jay O Boyle; Snehal G Patel; Benjamin R Roman; Christopher A Barker; Sean M McBride; Timothy A Chan; Snjezana Dogan; David M Hyman; Michael F Berger; David B Solit; Nadeem Riaz; Alan L Ho
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

9.  Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.

Authors:  J S Ross; L M Gay; K Wang; J A Vergilio; J Suh; S Ramkissoon; H Somerset; J M Johnson; J Russell; S Ali; A B Schrock; D Fabrizio; G Frampton; V Miller; P J Stephens; J A Elvin; D W Bowles
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

10.  Somatic mutations in salivary duct carcinoma and potential therapeutic targets.

Authors:  Timothy K Khoo; Bing Yu; Jonathan R Clark; Ruta Gupta; Joel A Smith; Angus J Clarke; Peter P Luk; Christina I Selinger; Kate L Mahon; Spiridoula Kraitsek; Carsten Palme; Michael J Boyer; Marcel E Dinger; Mark J Cowley; Sandra A O'Toole
Journal:  Oncotarget       Date:  2017-05-25
View more
  2 in total

1.  Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?

Authors:  Lisa M Rooper; Jeffrey Gagan; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-07-06

2.  Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

Authors:  Daisuke Kawakita; Toshitaka Nagao; Hideaki Takahashi; Satoshi Kano; Yoshitaka Honma; Hideaki Hirai; Natsuki Saigusa; Kohei Akazawa; Kaori Tani; Hiroya Ojiri; Kiyoaki Tsukahara; Hiroyuki Ozawa; Kenji Okami; Takahito Kondo; Takafumi Togashi; Chihiro Fushimi; Tomotaka Shimura; Akira Shimizu; Isaku Okamoto; Takuro Okada; Yorihisa Imanishi; Yoshihiro Watanabe; Kuninori Otsuka; Akihiro Sakai; Koji Ebisumoto; Yuichiro Sato; Keisuke Yamazaki; Yushi Ueki; Toyoyuki Hanazawa; Yuki Saito; Mizuo Ando; Takashi Matsuki; Masato Nakaguro; Yukiko Sato; Makoto Urano; Yoshitaka Utsumi; Shinji Kohsaka; Takashi Saotome; Yuichiro Tada
Journal:  Ther Adv Med Oncol       Date:  2022-09-06       Impact factor: 5.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.